Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari  Date: 2020-08-13

Medtronic to acquire Companion Medical to expand diabetes business

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical.

The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, which is the first US FDA-cleared smart insulin pen device combined with an optimized diabetes care app manufactured by the privately held company.

The introduction of the InPen to the Medtronic portfolio strengthens the company’s ability to provide a special and comprehensive service system, irrespective of how insulin is administered, to patients where they are in their progression through diabetes. 

Companion Medical's purchase builds on previous Medtronic acquisitions, including Nutrino and Klue, which form foundations for the construction of efficient algorithms that leverage the advanced data science and AI capabilities of the organization. 

Medtronic will collaborate through this new investment to further automate insights and dosing capacities to reduce affecting factors irrespective of the technology chosen for insulin transmission. Additionally, the deal assists Medtronic's plan extends to InPen's worldwide distribution.

Sources cite that the acquisition will be concluded within one to two months, provided all usual closing conditions are met. This is estimated that the deal would be favorable to, and accretive to, Medtronic's adjusted income per share during the current fiscal year. This will also follow the long-term financial benchmarks of Medtronic for acquisitions.

Sean Salmon, executive vice president and president of the Diabetes Group at Medtronic highlighted the firm's goal to find a trusted partner that offers support for an individual's preferences whether they want to stay on MDI, take on automated insulin or refrain from using their pump for some time. 

Highlighting the InPen, Sean said that the company is looking forward to expanding InPen's success by integrating it with smart algorithms to provide customized, constructive dosing guidance. This smart CGM machine can make people careless of diabetes and lead their own lives independently, he added.

Sean Saint, CEO, and co-founder of Companion Medical shared his excitement and stated that they are excited to bring together abilities and product offerings to support ever more diabetes-induced citizens around the globe.

Source Credit - https://www.businesswire.com/news/home/20200811005363/en/Bayer-Acquire-UK-Based-Biotech-KaNDy-Therapeutics-Ltd

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

RADCOM introduces automated assurance solution for 5G technology
RADCOM introduces automated assurance solution for 5G technology
By Akshay Kedari

5G technology has been in the headlines for quite a while. Next-generation technology has the potential to transform almost every sector across the world. However, as 5G becomes reality, it has become imperative for service providers to prevent degra...